Article Text

Download PDFPDF
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
  1. Virginia M. Rosen, PhD*,
  2. Ines Guerra,
  3. Mary McCormack, MD, PhD,
  4. Angélica Nogueira-Rodrigues, MD, PhD§,
  5. Andre Sasse, MD, PhD,
  6. Veronica C. Munk, PhD and
  7. Aijing Shang, MD, PhD
  1. * Optum, Eden Prairie, MN;
  2. Mapi Group, Uxbridge; and
  3. University College London Hospitals, London, UK;
  4. § Federal University, Belo Horizonte; and
  5. State University of Campinas, Campinas, Brazil; and
  6. F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  1. Address correspondence and reprint requests to Aijing Shang, MD, PhD, MORSE-HTA Group, Global Pricing and Market Access, Pharmaceuticals Division, F. Hoffmann-La Roche Ltd, Room 13.S643, Building 001, 4070 Basel, Switzerland. E-mail: aijing.shang{at}


Objective Despite advances in cervical cancer prevention and diagnosis, outcomes for patients given a diagnosis of advanced and recurrent disease are poor. In the GOG240 trial, the addition of bevacizumab to paclitaxel-topotecan or paclitaxel-cisplatin has been shown to prolong survival compared with paclitaxel-topotecan or paclitaxel-cisplatin in patients with persistent, recurrent, or metastatic disease. However, standards of care vary between regions and countries. The purpose of this systematic review and network meta-analysis was to enable a comparison between bevacizumab + chemotherapy with multiple monotherapy or combination chemotherapy regimens in the treatment for women with advanced, recurrent, or persistent cervical cancer.

Methods/Materials A systematic literature review was conducted to identify randomized or nonrandomized controlled trials of patients with recurrent, persistent, or metastatic cervical cancer published in English from 1999 to 2015. A feasibility study was performed to assess the heterogeneity of the trials, and a network meta-analysis was conducted. Fixed- and random-effects models were fitted to calculate the hazard ratio for overall survival (OS) for all pairwise comparisons and ranking of all interventions.

Results Twenty-three studies (19 trials) met inclusion criteria and were included in the review. Sample sizes ranged from 69 to 452, and median patient age ranged from 45 to 53 years. There was a trend toward prolonged OS with cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab compared with all non–bevacizumab-containing therapies. Cisplatin-paclitaxel-bevacizumab had the highest probability of being the most efficacious compared with all regimens (68.1%), and cisplatin monotherapy had the lowest (0%).

Conclusions The results of this network meta-analysis show that bevacizumab in combination with paclitaxel-topotecan or paclitaxel-cisplatin is likely to prolong OS over other non–bevacizumab-containing chemotherapies (eg, paclitaxel-carboplatin), which were not included in the GOG240 trial. In patients with advanced, persistent, and recurrent cervical cancer, cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab showed the highest efficacy in all regimens investigated in this analysis.

  • Cervical cancer
  • Angiogenesis inhibitors
  • Network meta-analysis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.